Hepatitis C and why the treatment is needed now? The summary report from the cross-border symposium of the 5th Tehran Hepatitis Congress May 2013

Hepatitis Monthly

Volumn 13, Issue 11, 2013, Pages

  Ebrahimi Daryani, Nasser ^a   Alavian, Seyed Moayed ^b,c   Somi, Mohammad Hossein ^d   Torabi Nami, Mohammad ^e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Middle East Liver Diseases Center (MELD Centers)   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis C; Iran; Management; Protease inhibitors

Indexed keywords

BOCEPREVIR; DACLATASVIR; ERYTHROPOIETIN; FALDAPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR;

ANEMIA; ANORECTAL DISEASE; ARTICLE; BURNING SENSATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DYSGEUSIA; FATIGUE; HEADACHE; HEPATITIS C; HUMAN; IRAN; NAUSEA; PRURITUS; RASH; SYMPOSIUM;

EID: 84888142360     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.16082     Document Type: Article

References (41)

1. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350-9.
2. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology. 2012;55(1):307-15.
3. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216-24.
4. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients;new indications for combination therapy. Hepat Mon. 2012;12(6):372-81.
5. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012;12(9).
6. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010;30(8):1173-80.
7. Poordad F, McCone JJr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-206.
8. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-17.
9. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2012;19(2):e134-42.
10. Cunningham M, Foster GR. Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol. 2012;5(2):139-51.
11. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433-44.
12. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64.
13. Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of chronic hepatitis C infection: update of the recommendations from scientific leader's meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011;11(9):703-13.
14. Burney T, Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti Infect Ther. 2011;9(2):151-60.
15. Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology. 2011;53(4):1090-9.
16. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705-16.
17. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with hcv-cirrhosis in a multicentre cohort of the french early access programme (anrs co20-cupic)-nct01514890. J hHepatol. 2013;59(3):434-41.
18. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-32.
19. Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol. 2013;59(3):434-41.
20. PegIntron®[package insert]. Whitehouse Station, NJ: Schering Corporation;2010.
21. Pegasys®[package insert]. South San Francisco, CA: Genentech, Inc.;2011.
22. Rebetol®[package insert]. Kenilworth, NJ: Schering Corporation;2003.
23. Copegus®[package insert]. South San Francisco, CA: Genentech, Inc.;2010.
24. Victrelis™ [package insert]. Whitehouse Station, NJ: Schering Corporation;2011.
25. Incivek™ [package insert]. Cambridge, MA: Vertex Pharmaceuticals Incorporated;2011.
26. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45-53.
27. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77.
28. Barreiro P, Vispo E, Poveda E, Fernandez-Montero JV, Soriano V. Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver. Clin Infect Dis. 2013;56(4):560-6.
29. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87.
30. Kwong AD, Kauffman RS, Hurter P, Mueller P. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotechnol. 2011;29(11):993-1003.
31. Venkatraman S. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. Trends Pharmacol Sci. 2012;33(5):289-94.
32. Bell TW. Drugs for hepatitis C: unlocking a new mechanism of action. ChemMedChem. 2010;5(10):1663-5.
33. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol. 2011;55(1):69-75.
34. Yamada I, Suzuki F, Kamiya N, Aoki K, Sakurai Y, Kano M, et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat. 2012;19(2):e112-9.
35. Vera-Llonch M, Martin M, Aggarwal J, Donepudi M, Bayliss M, Goss T, et al. Health-related quality of life in genotype 1 treatment-naive chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study. Aliment Pharmacol Ther. 2013.
36. Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Ebrahimi Daryani N, Nassiri Toosi M, et al. Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader's Meeting-28th July 2011-Tehran, IR Iran. Hepat Mon. 2011;11(9):703-13.
37. Telaprevir (Incivek) and boceprevir (Victrelis) for chronic hepatitis C. Med Lett Drugs Ther. 2011;53(1369):57-9.
38. Petta S, Craxi A. How to optimize HCV therapy in genotype 1 patients: predictors of response. Liver Int. 2013;33 Suppl 1:23-9.
39. Bourlière M, Wendt A, Fontaine H, Hézode C, Pol S, Bronowicki JP. How to optimize HCV therapy in genotype 1 patients with cirrhosis. Liver Int. 2013;33(1):46-55.
40. Camma C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850-60.
41. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54(3):439-48.